Thieler Law Corp, member of the Investor Attorney Network, is investigating whether members of the board of directors of Tobira Therapeutics Inc (NASDAQ: TBRA) acted responsibly on behalf of investors’ profitability in the planned $1.695 billion sale to Allergan plc.

On September 20, 2016, Tobira Therapeutics Inc (NASDAQ: TBRA) and Allergan plc announced that they had entered into a merger agreement. Under the terms of the merger agreement, Tobira stockholders will receive $28.35 per share, plus one non-transferrable contingent value right per share to receive one or more payments in cash of up to $49.84 per share total, contingent upon the achievement of certain milestones, for each share of Company common stock they own.

Based in San Francisco, CA, and founded in 2006 Tobira Therapeutics Inc focuses on the development and commercialization of therapeutics to treat liver disease, inflammation, fibrosis, and HIV.

The investigation focuses on whether NASDAQ: TBRA investors received the highest price and whether the directors of Tobira Therapeutics Inc acted in the best interest of Tobira Therapeutics Inc company and its shareholders.   

If you purchased Tobira Therapeutics Inc (NASDAQ: TBRA) prior to September 20, 2016, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185